(Q38506719)
Statements
1 reference
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). (English)
1 reference
Alberts DS
1 reference
Liu PY
1 reference
Wilczynski SP
1 reference
Jang A
1 reference
Moon J
1 reference
Ward JH
1 reference
Beck JT
1 reference
Clouser M
1 reference
Markman M
1 reference
5 March 2007
1 reference
1 reference
17
1 reference
4
1 reference
784-788
1 reference
Identifiers
1 reference
1 reference